Sp901
THE NEXT THERAPEUTIC FRONTIER IN IBD — WHERE ARE WE WITH TARGETING FIBROSIS?
Date
May 8, 2023
Explore related products in the following collection:
Society: AGA
Management of diseases of the ileo-anal pouch and perianal Crohn’s disease is challenging and involves multidisciplinary medical and surgical care. This session review the contemporary management of these complex clinical situations. It will also update the clinician and researcher on the emerging concepts of fibrosis as a therapeutic target as well as aging and frailty in in the management of IBD.
Management of diseases of the ileo-anal pouch and perianal Crohn’s disease is challenging and involves multidisciplinary medical and surgical care. This session review the contemporary management of these complex clinical situations. It will also update the clinician and researcher on the emerging concepts of fibrosis as a therapeutic target as well as aging and frailty in in the management of IBD.
Presenter
University of Michigan
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
CHANGES IN THERAPY ARE NOT ASSOCIATED WITH INCREASED REMISSION IN PATIENTS WITH CROHN’S DISEASE OF THE POUCH
BACKGROUND: Prevention of postoperative recurrence (POR) in Crohn’s disease (CD) after ileo-colonic (IC) resection is still a highly debated topic. Prophylactic immunosuppression after surgery is currently recommended in presence of at least one clinical risk factor (RF)…
PANEL DISCUSSION
Technology is pervasive and its role in healthcare continues to grow. This session will give attendees hand on tips to consider how three key technological innovations are transforming GI care: artificial intelligence, social media, electronic medical records and new endoscopic technology…
